



Recent Advances in Colorectal Cancer Screening

Guest Editors:

Dr. Andrea Burón

1. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
2. RICAPPS (Research Network on Chronicity, Primary Care and Health Promotion), Madrid, Spain

Dr. Gemma Binefa

1. Early Detection of Cancer Group, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
2. Ciber Salud Pública (CIBERESP), Instituto Salud Carlos III, Madrid, Spain

Deadline for manuscript submissions:

1 December 2024

Message from the Guest Editors

Dear Colleagues,

Colorectal cancer screening is nowadays widely carried out as an opportunistic intervention or as a population-based program. Although its efficacy is well documented, there are still many unanswered questions and challenges ahead. The fecal immunochemical test (FIT), sigmoidoscopy and colonoscopy are the most widely used screening and diagnostic tests, but more advanced and newer technologies are being proposed either as complementary or alternative tests in some settings. Biomarkers are one of these promising new technologies, although evidence of their effectiveness in real settings is still lacking.

This Special Issue aims to further advance the field of colorectal cancer screening via 1) increasing uptake and coverage rates; 2) reducing inequalities; 3) describing and tackling communication issues, enhancing informed participation; 4) proposing personalized screening strategies; 5) highlighting new screening and diagnostic tools. This Special Issue welcomes both original research articles and reviews.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)